Atreca Reports Second Quarter 2019 Financial Results and Recent Corporate Developments
REDWOOD CITY, Calif., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced financial results for the second quarter ended June 30, 2019, and provided an overview of Atreca’s recent developments.
“The second quarter of 2019 was a highly productive period for Atreca, highlighted by the completion of our successful initial public offering, which further strengthens our ability to execute on the promise of our differentiated technology platform drawn from a deep understanding of the human immune response,” said John Orwin, Chief Executive Officer. “We believe our lead product candidate, ATRC-101, represents an exciting and novel approach to cancer therapy with the potential to drive better outcomes for patients across a variety of solid tumors. We look forward to submitting the Investigational New Drug (IND) application for ATRC-101 later this year and initiating a Phase 1b clinical trial in patients with solid tumors in early 2020.”
Recent Developments and Highlights
- In June 2019, Atreca successfully completed its initial public offering, raising $130.8 million in net proceeds.
- In July 2019, Atreca further strengthened its management team with the appointments of Lisa L. Decker, Ph.D., as Chief Business Officer and Courtney J. Phillips as General Counsel.
- Atreca anticipates filing an IND application with the U.S. Food and Drug Administration for ATRC-101 in late 2019 and initiating a Phase 1b clinical trial in patients with solid tumors in early 2020.
Second Quarter 2019 Financial Results
- As of June 30, 2019, cash and cash equivalents and short-term investments totaled $219.7 million. This includes net proceeds of approximately $130.8 million from Atreca’s June 2019 initial public offering of common stock, after deducting the underwriting discounts and commissions and expenses of the offering.
- Research and development expenses for the three months ended June 30, 2019 were $15.9 million, including non-cash share-based compensation expense of $752,000.
- General and administrative expenses for the three months ended June 30, 2019 were $3.5 million, including non-cash share-based compensation expense of $607,000.
- Atreca reported a net loss of $17.9 million, or basic and diluted net loss per share attributable to common stockholders of $3.67, for the three months ended June 30, 2019.
About Atreca, Inc.
Atreca is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. Atreca’s discovery platform relies on the human immune system to discover unique antibody-target pairs from patients experiencing an active immune response against their tumors. These unique antibody-target pairs represent a potentially novel and previously unexplored landscape of immuno-oncology targets and provide the basis for novel clinical therapeutic candidates such as ATRC-101, the company’s lead clinical candidate. The company expects to file an Investigational New Drug application for ATRC-101 by the end of 2019 and to commence a Phase 1b study in multiple solid tumor types in early 2020. For more information on Atreca, please visit www.atreca.com.
This release contains forward-looking statements regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “will”, “expect,” “plan,” “anticipate,” “believe,” “estimate,” “potential,” and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and Investigational New Drug application and other regulatory submissions, and other matters that are described in our prospectus, dated June 19, 2019, as filed with the Securities and Exchange Commission (SEC) pursuant to Rule 424(b) under the Securities Act of 1933, as amended, which is available on the SEC’s website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
|June 30,||December 31,|
|Cash and cash equivalents||$||154,959||$||114,504|
|Prepaid expenses and other current assets||2,589||2,721|
|Total current assets||222,251||117,225|
|Property and equipment, net||4,155||4,143|
|Deposits and other||974||316|
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
|Other current liabilities||158||247|
|Total current liabilities||8,399||4,562|
|Capital lease obligations, net of current portion||77||100|
|Preferred stock warrant liability||—||380|
|Convertible preferred stock||—||209,669|
Stockholders’ equity (deficit)
|Additional paid-in capital||346,915||3,593|
|Accumulated other comprehensive loss||86||(4||)|
|Total stockholders’ equity (deficit)||218,882||(93,032||)|
|Total liabilities and stockholders’ equity (deficit)||$||227,380||$||121,684|
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
|Three Months Ended June 30,||Six Months Ended June 30,|
|Research and development||$||15,922||$||7,419||$||27,635||$||14,062|
|General and administrative||3,537||1,632||6,055||2,932|
|Interest and other income (expense)|
|Preferred stock warrant liability revaluation||(73||)||7||(123||)||27|
|Loss on disposal of property and equipment||(2||)||(1||)||(7||)||(1||)|
|Loss before income tax expense||(17,921||)||(8,667||)||(31,499||)||(16,323||)|
|Income tax expense||—||(1||)||(1||)||(1||)|
|Net loss per share, basic and diluted||$||(3.67||)||$||(4.13||)||$||(8.97||)||$||(7.79||)|
|Weighted-average shares used in computing net loss per share, basic and diluted||4,888,987||2,097,296||3,512,606||2,095,363|
Chief Financial Officer
Burns McClellan, Inc.
Robert Flamm, Ph.D. / Ryo Imai
212-213-0006 ext. 364 / 315
email@example.com / firstname.lastname@example.org
Alex Gray, 650-779-9251, ext. 251
Source: Atreca, Inc.